There's nothing new about the corporate quest to capitalize on growth in emerging economies. For GlaxoSmithKline (GSK -4.53%), which is increasing its stake in both in its Indian and Nigerian consumer health businesses, emerging economies provide an opportunity to boost otherwise stagnant revenue trends within its core pharmaceuticals business in the U.S. and Europe. In the following video, health care bureau chief Brenton Flynn runs through the Glaxo news and highlights some other big pharma players targeting emerging markets to spur growth going forward: Johnson & Johnson (JNJ -0.99%) and Abbott Laboratories (ABT -8.25%).